[
  {
    "ts": null,
    "headline": "BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug",
    "summary": "BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.",
    "url": "https://finnhub.io/api/news?id=b2e3405548c48975de7f722f6e0d18102fe3303adf60d79fca2dcdc5c0b56043",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732569372,
      "headline": "BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug",
      "id": 131627592,
      "image": "https://media.zenfs.com/en/ibd.com/703850409d67abc5aa561ec3cc7d1f01",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.",
      "url": "https://finnhub.io/api/news?id=b2e3405548c48975de7f722f6e0d18102fe3303adf60d79fca2dcdc5c0b56043"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Rises After Leerink Partners Upgrades Its Rating",
    "summary": "Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.",
    "url": "https://finnhub.io/api/news?id=65ca21afd797240f947e2a0cb18f813360149febcbdc3a2c884e9a5483a1d1fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732564800,
      "headline": "AbbVie Stock Rises After Leerink Partners Upgrades Its Rating",
      "id": 131637891,
      "image": "https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.",
      "url": "https://finnhub.io/api/news?id=65ca21afd797240f947e2a0cb18f813360149febcbdc3a2c884e9a5483a1d1fb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=cb5a158e3cfc3c16829091fdcfddbb201687360dcbfdfc104ec71aae335c0ee8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732552800,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 131638915,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=cb5a158e3cfc3c16829091fdcfddbb201687360dcbfdfc104ec71aae335c0ee8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Schlumberger are January Bounce Candidates",
    "summary": "Stocks that struggled in 2024 but may bounce to start 2025",
    "url": "https://finnhub.io/api/news?id=28fbe7614d4491c82d9192668e939cdf5d5721298e8c0ccda0767e9820e351fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732552280,
      "headline": "Pfizer and Schlumberger are January Bounce Candidates",
      "id": 131646206,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/257f26372f51852459eab20ee046278f",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stocks that struggled in 2024 but may bounce to start 2025",
      "url": "https://finnhub.io/api/news?id=28fbe7614d4491c82d9192668e939cdf5d5721298e8c0ccda0767e9820e351fb"
    }
  },
  {
    "ts": null,
    "headline": "BridgeBio Soars After Drug Gets Nod in Rare Heart Condition",
    "summary": "(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of heart disease, paving the way for head-to-head competition with medications from Pfizer Inc.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets Historic Push for 80,000 Homes With $5",
    "url": "https://finnhub.io/api/news?id=222fd579fe60904aca367411750bb169b4a60421a55189d1dfcdbec679fbe56b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732545622,
      "headline": "BridgeBio Soars After Drug Gets Nod in Rare Heart Condition",
      "id": 131646208,
      "image": "https://s.yimg.com/ny/api/res/1.2/flbn9WibOm8oIhNPKtaVUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/306b0a3efa17279181795656cf7c2a5c",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- BridgeBio Pharma Inc. jumped the most in 16 months after its drug got US regulators’ nod to treat a rare, deadly form of heart disease, paving the way for head-to-head competition with medications from Pfizer Inc.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets Historic Push for 80,000 Homes With $5",
      "url": "https://finnhub.io/api/news?id=222fd579fe60904aca367411750bb169b4a60421a55189d1dfcdbec679fbe56b"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market",
    "summary": "On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on ATTRibute-CM Phase 3 study results, which showed that Attruby significantly reduced death and cardiovascular-related hospitalization and improved quality of life. Also Read: BridgeBio Pharma’s Acoramidis S",
    "url": "https://finnhub.io/api/news?id=09e0de56a10fd87dd90dbcf57baa38182d03c4de209a98408be6223830815cc8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732543426,
      "headline": "FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market",
      "id": 131646210,
      "image": "https://media.zenfs.com/en/Benzinga/f8141477683f51201c3e739694e8d073",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ:BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on ATTRibute-CM Phase 3 study results, which showed that Attruby significantly reduced death and cardiovascular-related hospitalization and improved quality of life. Also Read: BridgeBio Pharma’s Acoramidis S",
      "url": "https://finnhub.io/api/news?id=09e0de56a10fd87dd90dbcf57baa38182d03c4de209a98408be6223830815cc8"
    }
  },
  {
    "ts": null,
    "headline": "Finding Winners In Biotech, Probably The Riskiest Sector",
    "summary": "Jonathan Faison shares his approach to investing in biotech, the 'riskiest' sector. Recent lows and seeing through the volatility.",
    "url": "https://finnhub.io/api/news?id=7c4d77f24653ebbe6e97ec170651bdb1659f6bcbb787689530bddbca7cce4392",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732541400,
      "headline": "Finding Winners In Biotech, Probably The Riskiest Sector",
      "id": 131625800,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Jonathan Faison shares his approach to investing in biotech, the 'riskiest' sector. Recent lows and seeing through the volatility.",
      "url": "https://finnhub.io/api/news?id=7c4d77f24653ebbe6e97ec170651bdb1659f6bcbb787689530bddbca7cce4392"
    }
  }
]